Menu
Imagine Oral Vaccines
Oravax is developing
breakthrough technologies for the oral delivery of vaccines
Imagine Oral Vaccines
Oravax is developing
breakthrough technologies for the
oral delivery of vaccines
Menu
Find out what our technology can do
Oral administration of vaccines is not only the most patient-friendly route, it also improves vaccine efficacy through better accessibility and compliance. Oral delivery should significantly lower the cost of administration and help encourage a larger percentage of the population to get vaccinated.
- Problem
Due to the inherent hurdles presented by the digestive system, an exceptionally small fraction of vaccines are available in an oral format.
- Solution
Oravax is developing an oral Covid-19 vaccine. The Oravax technology seamlessly integrates a novel approach to vaccines from Premas Biotech based on their D-Crypt™ technology with an oral delivery platform from Oramed Pharmaceuticals based on their proprietary POD™ delivery technology.
Triple antigen – a more promising vaccine candidate for protection against COVID-19 variants
Targets 3 SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, making our vaccine a better candidate to provide protection even against emerging mutated viruses.
Demonstrated (in preclinical and GLP-Tox studies) to be safe, efficacious and well tolerated at normal to high doses, and generates high titres of neutralizing antibodies
Oral vaccine should improve efficacy, takes burden off health care systems
- Cuts out the need for freezing equipment for transportation & storage
- Easy accessibility results in better population coverage (especially for those who fear needles)
- Minimizes cost of training and mobilizing health care personnel
- Eliminates occupational needle-stick injuries
- Eliminates bio-hazardous waste problem
In a pilot animal study, the oral COVID-19 vaccine promoted both systemic immunity through Immunoglobulin G (IgG), the most common antibody in blood and bodily fluids that protects against viral infections, and Immunoglobulin A (IgA), which protects the respiratory and gastrointestinal tracts against infection.
Triple antigen – a more promising vaccine candidate for protection against COVID-19 variants
Targets 3 SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, making our vaccine a better candidate to provide protection even against emerging mutated viruses.
Demonstrated (in preclinical and GLP-Tox studies) to be safe, efficacious and well tolerated at normal to high doses, and generates high titres of neutralizing antibodies
Oral vaccine should improve efficacy, takes burden off health care systems
- Cuts out the need for freezing equipment for transportation & storage
- Easy accessibility results in better population coverage (especially for those who fear needles)
- Minimizes cost of training and mobilizing health care personnel
- Eliminates occupational needle-stick injuries
- Eliminates bio-hazardous waste problem
Clinical trial preparations are underway with studies expected to commence H2 2021
In a pilot animal study, the oral COVID-19 vaccine promoted both systemic immunity through Immunoglobulin G (IgG), the most common antibody in blood and bodily fluids that protects against viral infections, and Immunoglobulin A (IgA), which protects the respiratory and gastrointestinal tracts against infection.
about us
Oravax is based on cutting edge technology from
Oramed Pharmaceuticals & Premas Biotech.
Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Oramed’s proprietary Protein Oral Delivery (POD™) technology allows for the oral delivery of therapeutic proteins and vaccines.
Premas Biotech is an innovative developer and manufacturer of novel biotherapeutic & vaccine candidates. Premas’ key areas of focus include: infectious diseases, cancer, metabolic disorders and inflammation. Premas’s novel D-Crypt™ platform technology focuses on difficult to express proteins .